DOP2016000102A - (aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso - Google Patents
(aza)piridopirazolopirimidinonas e indazolopirimidinonas y su usoInfo
- Publication number
- DOP2016000102A DOP2016000102A DO2016000102A DO2016000102A DOP2016000102A DO P2016000102 A DOP2016000102 A DO P2016000102A DO 2016000102 A DO2016000102 A DO 2016000102A DO 2016000102 A DO2016000102 A DO 2016000102A DO P2016000102 A DOP2016000102 A DO P2016000102A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- aza
- bleeding
- hereditary
- piridopirazolopirimidinonas
- indazolopirimidinonas
- Prior art date
Links
- 230000000740 bleeding effect Effects 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010019860 Hereditary angioedema Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 201000004595 synovitis Diseases 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRESENTE SOLICITUD SE RELACIONA CON NUEVAS (AZA)PIRIDOPIRAZOLOPIRIMIDINONAS E INDAZOLOPIRIMIDINONAS SUSTITUIDAS, CON PROCESOS PARA SU PREPARACIÓN, EN DONDE LOS COMPUESTOS SE USAN SOLOS O EN COMBINACIONES EN UN MÉTODO PARA EL TRATAMIENTO Y/O PROFILAXIS DE ENFERMEDADES, EN PARTICULAR PARA EL TRATAMIENTO Y/O PROFILAXIS DE SANGRADO AGUDO Y RECURRENTE EN PACIENTES CON O SIN TRASTORNOS DE SANGRADO HEREDITARIOS O ADQUIRIDOS SUBYACENTES, EN DONDE EL SANGRADO ESTÁ ASOCIADO CON UNA ENFERMEDAD O INTERVENCIÓN MÉDICA QUE SE ELIGE DEL GRUPO QUE CONSISTE EN MENORRAGIA, HEMORRAGIA POSPARTO, CHOQUE HEMORRÁGICO, TRAUMA, CIRUGÍA, TRASPLANTE, INFARTO, ENFERMEDADES HEPÁTICAS, ANGIOEDEMA HEREDITARIO, SANGRADO DE NARIZ, Y SINOVITIS Y DAÑO DE CARTÍLAGO LUEGO DE HEMARTROSIS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13191642 | 2013-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2016000102A true DOP2016000102A (es) | 2016-06-30 |
Family
ID=49517406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2016000102A DOP2016000102A (es) | 2013-11-05 | 2016-05-05 | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US9598417B2 (es) |
| EP (1) | EP3066100B1 (es) |
| JP (1) | JP6431061B2 (es) |
| KR (1) | KR102312780B1 (es) |
| CN (1) | CN105683194B (es) |
| AP (1) | AP2016009175A0 (es) |
| AR (1) | AR098292A1 (es) |
| AU (1) | AU2014345771B2 (es) |
| CA (1) | CA2929378C (es) |
| CL (1) | CL2016001076A1 (es) |
| CR (1) | CR20160332A (es) |
| CU (1) | CU24361B1 (es) |
| DO (1) | DOP2016000102A (es) |
| EA (1) | EA029373B1 (es) |
| ES (1) | ES2732305T3 (es) |
| GT (1) | GT201600084A (es) |
| IL (1) | IL244645B (es) |
| MA (1) | MA39018A1 (es) |
| MX (1) | MX370419B (es) |
| PE (1) | PE20160934A1 (es) |
| PH (1) | PH12016500828A1 (es) |
| SG (1) | SG11201602133RA (es) |
| TN (1) | TN2016000161A1 (es) |
| TW (1) | TWI657089B (es) |
| UA (1) | UA117504C2 (es) |
| UY (1) | UY35809A (es) |
| WO (1) | WO2015067549A1 (es) |
| ZA (1) | ZA201602311B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY35809A (es) * | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
| EP3215505B1 (en) * | 2014-11-03 | 2019-07-24 | Bayer Pharma Aktiengesellschaft | Piperidinylpyrazolopyrimidinones and their use |
| WO2016173948A1 (en) * | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Indazolopyrimidinones as fibrinolysis inhibitors |
| WO2017007917A1 (en) * | 2015-07-07 | 2017-01-12 | Mast Therapeutics, Inc. | Polyoxyethylene/polyoxypropylene copolymers and fibrinolytic inhibitors, uses thereof and compositions |
| EP3318563A1 (en) | 2016-11-07 | 2018-05-09 | Sanofi | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
| CN110590673A (zh) * | 2019-09-02 | 2019-12-20 | 南通大学 | 一种4-氯-7-甲基-1h-吲唑及其化学合成方法 |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11654057B2 (en) | 2020-04-09 | 2023-05-23 | Bio 54, Llc | Devices for bleeding reduction and methods of making and using the same |
| CN121248675A (zh) | 2020-12-31 | 2026-01-02 | 赛诺哈勃药业（成都）有限公司 | 一种纤溶酶抑制剂、其制备方法及应用 |
| JP7749679B2 (ja) * | 2021-02-05 | 2025-10-06 | シンノハブ ファーマシューティカル カンパニー，リミティド | プラスミン阻害剤、その製造方法およびその適用 |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| CN117500799A (zh) | 2021-06-09 | 2024-02-02 | 伊莱利利公司 | 作为kras g12d抑制剂的取代的稠合吖嗪 |
| US11642324B1 (en) | 2022-03-01 | 2023-05-09 | Bio 54, Llc | Topical tranexamic acid compositions and methods of use thereof |
| TW202404601A (zh) | 2022-04-05 | 2024-02-01 | 加拿大商索科普拉健康與人類科學兩合公司 | 用於選擇性消退血栓性或血栓栓塞性疾病中血栓的凝乳酶抑制劑 |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2192559A5 (en) * | 1972-07-17 | 1974-02-08 | Ugine Kuhlmann | Pyrimidino (1,2-b) indazole derivs - inters for dyes and pharmaceuticals, from 3-aminoindazoles and beta-ketone derivs |
| JP5205053B2 (ja) | 2004-07-30 | 2013-06-05 | フェリング ビー．ブイ． | トラネキサム酸製剤 |
| AR059224A1 (es) * | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
| MX2010012793A (es) * | 2008-06-06 | 2010-12-14 | Sanofi Aventis | Derivados de urea macrociclicos y de sulfamida como inhibidores de tafia. |
| EP2413932A4 (en) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | HAMMER OF ACT ACTIVITY |
| UY32543A (es) | 2009-04-07 | 2010-11-30 | Astrazeneca Ab | Análogos de isoxazol-3(2h)-ona como agentes terapéuticos |
| WO2012047156A1 (en) * | 2010-10-04 | 2012-04-12 | Astrazeneca Ab | Isoxazol-3(2h)-one analogs as plasminogen inhibitors and their use in the treatment of fibrinolysis related diseases |
| KR20140003438A (ko) * | 2010-11-15 | 2014-01-09 | 카톨리에케 유니버시테이트 루벤 | 항바이러스성 축합 헤테로사이클릭 화합물 |
| WO2012080237A1 (en) * | 2010-12-16 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway |
| WO2012082947A1 (en) * | 2010-12-16 | 2012-06-21 | Irm Llc | Compounds and compositions as tgr5 agonists |
| UY35809A (es) * | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
| WO2016173948A1 (en) * | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Indazolopyrimidinones as fibrinolysis inhibitors |
-
2014
- 2014-10-31 UY UY0001035809A patent/UY35809A/es not_active Application Discontinuation
- 2014-11-03 MA MA39018A patent/MA39018A1/fr unknown
- 2014-11-03 PE PE2016000586A patent/PE20160934A1/es unknown
- 2014-11-03 JP JP2016527398A patent/JP6431061B2/ja not_active Expired - Fee Related
- 2014-11-03 EA EA201690935A patent/EA029373B1/ru not_active IP Right Cessation
- 2014-11-03 UA UAA201605980A patent/UA117504C2/uk unknown
- 2014-11-03 CN CN201480060660.7A patent/CN105683194B/zh not_active Expired - Fee Related
- 2014-11-03 EP EP14793523.3A patent/EP3066100B1/en active Active
- 2014-11-03 MX MX2016005969A patent/MX370419B/es active IP Right Grant
- 2014-11-03 TN TN2016000161A patent/TN2016000161A1/en unknown
- 2014-11-03 WO PCT/EP2014/073529 patent/WO2015067549A1/en not_active Ceased
- 2014-11-03 TW TW103137976A patent/TWI657089B/zh not_active IP Right Cessation
- 2014-11-03 CA CA2929378A patent/CA2929378C/en not_active Expired - Fee Related
- 2014-11-03 KR KR1020167014622A patent/KR102312780B1/ko not_active Expired - Fee Related
- 2014-11-03 SG SG11201602133RA patent/SG11201602133RA/en unknown
- 2014-11-03 AP AP2016009175A patent/AP2016009175A0/en unknown
- 2014-11-03 CU CU2016000062A patent/CU24361B1/es unknown
- 2014-11-03 ES ES14793523T patent/ES2732305T3/es active Active
- 2014-11-03 CR CR20160332A patent/CR20160332A/es unknown
- 2014-11-03 AU AU2014345771A patent/AU2014345771B2/en not_active Ceased
- 2014-11-04 AR ARP140104130A patent/AR098292A1/es not_active Application Discontinuation
- 2014-11-05 US US14/533,915 patent/US9598417B2/en not_active Expired - Fee Related
-
2016
- 2016-03-17 IL IL244645A patent/IL244645B/en active IP Right Grant
- 2016-04-06 ZA ZA2016/02311A patent/ZA201602311B/en unknown
- 2016-05-04 PH PH12016500828A patent/PH12016500828A1/en unknown
- 2016-05-05 GT GT201600084A patent/GT201600084A/es unknown
- 2016-05-05 CL CL2016001076A patent/CL2016001076A1/es unknown
- 2016-05-05 DO DO2016000102A patent/DOP2016000102A/es unknown
-
2017
- 2017-01-26 US US15/416,651 patent/US10098883B2/en active Active
-
2018
- 2018-08-10 US US16/101,250 patent/US10668071B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201600084A (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas y su uso | |
| MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| IL262591A (en) | Methods for treating patients with familial hypercholesterolemia | |
| MX2020007060A (es) | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas. | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| MX2020009602A (es) | Formulaciones de pulverizacion de epinefrina. | |
| BR112015009948A8 (pt) | Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios | |
| CO2017004715A2 (es) | Métodos y formulaciones para tratar enfermedades vasculares de los ojos | |
| MX2015009104A (es) | Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares. | |
| CR20160222U (es) | Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas | |
| CR11731A (es) | Composiciones y procedimientos para su preparación y uso | |
| MX2021014242A (es) | Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora. | |
| JOP20200231A1 (ar) | ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها | |
| AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
| MX2017006113A (es) | Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh). | |
| BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
| MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
| EA201692402A1 (ru) | Лекарственные формы для местного применения и их использование | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112016028895A2 (pt) | composições biofotônicas termofixas e usos destas | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| MX2015012315A (es) | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. | |
| BR112018008769A2 (pt) | formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída | |
| MX2019007555A (es) | Uso de bacterias de acido láctico para tratar o prevenir la diabetes mellitus gestacional. | |
| BR112017020013A2 (pt) | método para preparação de um substituto da pele, substituto da pele, substituto dérmico, enxerto, enxerto para uso, e kit para implementação do método |